Stockreport

Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy

Cytokinetics, Incorporated  (CYTK) 
Last cytokinetics, incorporated earnings: 3/3 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.cytokinetics.com/investor-overview
PDF Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater Chi [Read more]